for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Merck's Keytruda Combination Therapy Met Main Goal In Metastatic Triple-Negative Breast Cancer Study

Feb 12 (Reuters) - Merck & Co Inc:

* MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY MET PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL (PFS) AS FIRST-LINE TREATMENT FOR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (MTNBC)

* MERCK - KEYTRUDA PLUS CHEMOTHERAPY SIGNIFICANTLY IMPROVED PFS COMPARED TO CHEMOTHERAPY ALONE IN PATIENTS WITH MTNBC WHOSE TUMORS EXPRESSED PD-L1

* MERCK & CO - SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT WITH THAT OBSERVED IN PREVIOUSLY REPORTED STUDIES

* MERCK - FIRST-LINE TREATMENT WITH KEYTRUDA IN COMBINATION WITH CHEMOTHERAPY DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS

* MERCK & CO INC - NO NEW SAFETY SIGNALS WERE IDENTIFIED IN PHASE 3 STUDY OF KEYTRUDA Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up